

Table 1.9a
Immunosuppression Use by Organ in 2007 and 2008

	Organ								
	Heart-Lung	Heart	Intest-ine	Kidney	KP	Liver	Lung	PAK	PTA
Transplants (2008)	27	2,163	185	16,517	836	6,318	1,478	214	223
Tx With Immunosuppression Info at Discharge	22	2,110	182	16,250	823	6,125	1,436	206	219
Induction Drug Reported	72.7%	52.3%	59.9%	81.5%	83.4%	26.6%	62.7%	79.6%	73.1%
Induction Drugs									
Atgam/NRATG/NRATS	13.6%	6.5%	0.0%	1.5%	1.5%	1.1%	7.1%	1.0%	1.4%
OKT3	0.0%	1.4%	15.4%	1.0%	1.0%	2.5%	0.7%	1.0%	6.4%
Thymoglobulin	0.0%	18.1%	33.5%	44.8%	59.8%	10.3%	4.5%	51.9%	49.8%
Zenapax	40.9%	11.1%	8.2%	10.9%	6.1%	7.9%	14.0%	4.4%	6.8%
Simulect	4.5%	14.0%	0.5%	17.8%	8.4%	6.7%	28.8%	8.3%	4.6%
Campath	13.6%	3.4%	18.1%	10.7%	9.8%	1.0%	9.2%	15.0%	11.4%
Tx With Immunosuppression Info and Functioning Graft at Discharge	20	2,026	167	16,000	815	5,826	1,358	192	201
Maintenance at Discharge									
Corticosteroids Use	100.0%	87.4%	78.4%	66.2%	70.1%	80.0%	98.2%	59.9%	56.7%
Steroids	100.0%	87.4%	78.4%	66.2%	70.1%	80.0%	98.2%	59.9%	56.7%
Calcineurin Inhibitor Use	100.0%	98.7%	100.0%	95.9%	98.4%	98.0%	98.9%	96.9%	99.0%
Cyclosporine	10.0%	25.6%	0.6%	7.6%	4.4%	7.0%	8.4%	3.6%	1.5%
Tacrolimus	90.0%	72.5%	98.8%	87.8%	93.3%	90.4%	89.3%	92.7%	97.5%
Everolimus	0.0%	0.6%	0.6%	0.5%	0.7%	0.6%	1.2%	0.5%	0.0%
Antimetabolite Use	95.0%	92.5%	24.6%	93.4%	91.2%	77.0%	91.4%	93.8%	62.2%
Mycophenolate Mofetil	85.0%	87.1%	24.0%	74.1%	72.5%	71.3%	54.3%	79.2%	55.7%
Mycophenolate Sodium	5.0%	2.7%	0.0%	18.5%	18.5%	5.3%	8.7%	13.0%	6.0%
Azathioprine	5.0%	2.8%	0.6%	0.8%	0.1%	0.4%	28.4%	1.0%	0.5%
Leflunomide	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.5%	0.0%
mTOR Inhibitor Use	0.0%	3.4%	9.6%	4.1%	8.0%	2.2%	0.4%	7.8%	10.9%
Sirolimus	0.0%	1.0%	9.6%	4.1%	8.0%	2.1%	0.4%	7.8%	10.9%
Everolimus	0.0%	2.4%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Transplants (2007)	31	2,209	198	16,630	862	6,494	1,471	261	208
Tx With Maintenance Use at 1yr PostTx	26	1,896	139	14,693	755	5,131	1,150	206	150
Maintenance at 1yr PostTx									
Corticosteroids Use	100.0%	66.0%	68.3%	64.1%	67.5%	35.1%	98.6%	55.3%	53.3%
Steroids	100.0%	66.0%	68.3%	64.1%	67.5%	35.1%	98.6%	55.3%	53.3%
Calcineurin Inhibitor Use	100.0%	97.1%	98.6%	94.1%	97.9%	92.7%	98.2%	97.1%	96.7%
Cyclosporine	7.7%	27.8%	1.4%	9.7%	6.9%	8.2%	9.8%	5.3%	2.7%
Tacrolimus	92.3%	68.9%	96.4%	84.0%	90.6%	84.2%	87.8%	90.8%	94.0%
Everolimus	0.0%	0.4%	0.7%	0.5%	0.4%	0.4%	0.5%	1.0%	0.0%
Antimetabolite Use	57.7%	88.1%	10.1%	88.4%	84.8%	49.6%	80.2%	87.9%	56.7%
Mycophenolate Mofetil	46.2%	75.7%	8.6%	65.6%	62.1%	43.0%	48.8%	70.4%	46.7%
Mycophenolate Sodium	3.8%	6.9%	0.0%	20.7%	21.2%	5.8%	8.8%	15.0%	8.0%
Azathioprine	7.7%	5.4%	1.4%	1.4%	1.1%	0.8%	22.5%	1.0%	2.0%
Leflunomide	0.0%	0.1%	0.0%	0.7%	0.4%	0.0%	0.1%	1.5%	0.0%
mTOR Inhibitor Use	3.8%	9.3%	6.5%	8.3%	13.9%	8.3%	6.6%	18.0%	20.0%
Sirolimus	3.8%	6.9%	6.5%	8.0%	13.9%	8.3%	6.6%	18.0%	20.0%

(Continued)

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.
Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.

Table 1.9a (Continued)
Immunosuppression Use by Organ in 2007 and 2008

	Organ								
	Heart-Lung	Heart	Intest-ine	Kidney	KP	Liver	Lung	PAK	PTA
Maintenance at 1yr PostTx mTOR Inhibitor Use Everolimus	0.0%	2.5%	0.0%	0.3%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category. Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.